CNS involvement in Mantle-cell lymphoma

被引:57
|
作者
Montserrat, E
Bosch, F
LopezGuillermo, A
Graus, F
Terol, MJ
Campo, E
Rozman, C
机构
[1] UNIV BARCELONA,HOSP CLIN,DEPT NEUROL,E-08036 BARCELONA,SPAIN
[2] UNIV BARCELONA,HOSP CLIN,DEPT PATHOL,E-08036 BARCELONA,SPAIN
关键词
D O I
10.1200/JCO.1996.14.3.941
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: In non-Hodgkin's lymphomas, CNS involvement is highly dependent on the histology of the lymphoma, Mantle-cell lymphoma (MCL) is a lymphoma type with distinctive histologic, biologic, and clinical features in which CNS involvement has only been rarely described. The purpose of this report is to describe the incidence, clinical characteristics, and outcome of CNS infiltration in patients with MCL seen at a single institution. Patients and Methods: Twenty-two patients with MCL, who account for 6% of all patients with nodal lymphomas diagnosed and monitored at a university hospital from 1987 to 1994, were studied. Analysis of the incidence of CNS involvement by the disease was performed. Results: Five of 22 patients (22%; exact 95% confidence interval [CI], 7.8% to 45.4%) with MCL developed CNS involvement at a median of 18 months (range, 6 to 59) from diagnosis, All of these patients presented with poor MCL histologic subtypes and advanced disease, When the CNS infiltration became apparent, all of the patients displayed neurologic signs and had lymphoid cells consistent with the diagnosis of MCL in the CSF, In most of the cases, CNS infiltration was part of resistant disease or generalised relapse and had an ominous significance. Conclusion: The incidence of CNS involvement in MCL might be higher than previously recognized. The frequency of CNS infiltration in MCL deserves to be investigated in other series and, if a high incidence is confirmed, the risk factors, mechanisms, and clinical implications of such a complication should be further studied. (C) 1996 by American Society of Clinical Oncology,
引用
收藏
页码:941 / 944
页数:4
相关论文
共 50 条
  • [41] Is rituximab effective as a single agent in mantle-cell lymphoma?
    Grillo-López, AJ
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (10): : 500 - 501
  • [42] Is rituximab effective as a single agent in mantle-cell lymphoma?
    Antonio J Grillo-López
    Nature Clinical Practice Oncology, 2005, 2 : 500 - 501
  • [43] High-dose chemotherapy in mantle-cell lymphoma
    Krüger, N
    Hoffknecht, M
    Schmitz, N
    Krüger, W
    Zander, AR
    BONE MARROW TRANSPLANTATION, 1998, 22 : S27 - S27
  • [44] Bortezomib-Based Therapy for Mantle-Cell Lymphoma
    Sengar, Manju
    Jain, Hasmukh
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (23): : 2270 - 2271
  • [45] Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
    Tam, Constantine S.
    Anderson, Mary Ann
    Pott, Christiane
    Agarwal, Rishu
    Handunnetti, Sasanka
    Hicks, Rodney J.
    Burbury, Kate
    Turner, Gillian
    Di Iulio, Juliana
    Bressel, Mathias
    Westerman, David
    Lade, Stephen
    Dreyling, Martin
    Dawson, Sarah-Jane
    Dawson, Mark A.
    Seymour, John F.
    Roberts, Andrew W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1211 - 1223
  • [46] Inactivated ATM gene involved in mantle-cell lymphoma
    Burton, A
    LANCET ONCOLOGY, 2002, 3 (03): : 130 - 130
  • [47] Lenalidomide plus Rituximab for Mantle-Cell Lymphoma REPLY
    Ruan, Jia
    Leonard, John P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (08): : 793 - 793
  • [48] INCIDENCE, CHARACTERISTICS AND OUTCOME OF CNS INVOLVEMENT IN MANTLE CELL LYMPHOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS FROM THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK
    Cheah, C.
    George, A.
    Gine, E.
    Kluin-Nelemans, J.
    Klener, P.
    Mocikova, H.
    Salek, D.
    Walewski, J.
    Szymczyk, M.
    Smolej, L.
    Jurczak, W.
    Chiappella, A.
    Mosurska, K.
    Auer, R.
    Williams, M.
    Ritchie, D.
    Dreyling, M.
    Seymour, J.
    HAEMATOLOGICA, 2012, 97 : 457 - 457
  • [49] An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma
    Morabito, Fortunato
    Recchia, Anna Grazia
    Vigna, Ernesto
    Botta, Cirino
    Skafi, Mamdouh
    Abu-Rayyan, Mohammed
    Atrash, Moien
    Galimberti, Sara
    Morabito, Lucio
    Al-Janazreh, Hamdi
    Martino, Massimo
    Cutrona, Giovanna
    Gentile, Massimo
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (01) : 29 - 38
  • [50] Development of a murine model for blastoid variant mantle-cell lymphoma
    Ford, Richard J.
    Shen, Long
    Lin-Lee, Yen Chiu
    Pham, Lan V.
    Multani, Asha
    Zhou, Hai-Jun
    Tamayo, Archito T.
    Zhang, ChongJie
    Hawthorn, Lesleyann
    Cowell, John K.
    Ambrus, Julian L., Jr.
    BLOOD, 2007, 109 (11) : 4899 - 4906